Mechanism of Action of Calcium Polystyrene Sulfonate
Calcium polystyrene sulfonate (CPS) is a cation-exchange resin that binds potassium ions in the gastrointestinal tract (primarily the colon) in exchange for calcium ions, thereby increasing fecal potassium excretion and lowering serum potassium levels. 1
How the Exchange Process Works
CPS functions as a nonabsorbed polymer that operates through ion exchange in the intestinal lumen 1:
- The resin releases calcium ions (Ca²⁺) as it binds potassium ions (K⁺) from the gastrointestinal contents
- This exchange occurs predominantly in the colon, where the resin has sufficient contact time with intestinal fluid 1
- The bound potassium is then eliminated in the feces, effectively removing it from the body 1
Key Pharmacological Characteristics
Selectivity and Binding Properties
CPS is nonselective for potassium and also binds other cations including magnesium (Mg²⁺) and sodium (Na⁺) 1. This nonselective binding can lead to electrolyte disturbances beyond potassium reduction.
Onset and Duration
- Onset of action: Variable, typically several hours 1
- The potassium-lowering effect is not immediate, making CPS unsuitable as monotherapy for life-threatening hyperkalemia 2
- Clinical studies show measurable reductions in serum potassium within 24 hours, with continued effect over days to weeks 3, 4
Exchange Capacity
The in-vitro exchange capacity is approximately 3.1 mEq of potassium per gram of resin, though the in-vivo capacity is lower at approximately 1 mEq per gram 2.
Clinical Efficacy Evidence
Recent comparative studies demonstrate CPS effectively reduces serum potassium by 0.5-1.0 mEq/L over treatment periods ranging from days to weeks 5, 6, 3:
- In hemodialysis patients, CPS (15 g/day) significantly reduced serum potassium from 5.88 to 5.12 mmol/L over 12 weeks 3
- A crossover study in pre-dialysis patients showed CPS reduced potassium without the adverse metabolic effects seen with sodium polystyrene sulfonate 6
Advantages Over Sodium Polystyrene Sulfonate
CPS offers a critical safety advantage by exchanging calcium instead of sodium, thereby avoiding sodium loading and volume overload 7, 6:
- No sodium content (compared to 1500 mg sodium per 15-g dose of SPS) 1
- Avoids hypervolemia risk, making it safer for patients with heart failure or hypertension 7, 6
- Does not induce secondary hyperparathyroidism, unlike SPS which can cause hypocalcemia and elevated PTH 6
- Recent data suggest SPS increases heart failure risk (HR 1.24), particularly in elderly patients, while CPS does not carry this sodium-related risk 8
Important Clinical Caveats
Limitations in Acute Settings
CPS should not be used as sole therapy for severe or life-threatening hyperkalemia (K⁺ >6.5 mEq/L or with ECG changes) due to its delayed onset 9, 2. In emergencies, use:
- IV calcium for membrane stabilization
- Insulin/glucose and beta-agonists for intracellular potassium shift
- Consider hemodialysis for definitive removal
Gastrointestinal Safety Concerns
While serious GI complications (intestinal necrosis, ischemic colitis) have been reported with polystyrene resins, these events are primarily associated with SPS, especially when combined with sorbitol 1, 2. The absolute risk remains low (16-23 events per 1000 person-years) 5.
Avoid CPS in patients with:
- Bowel obstruction or ileus
- Recent abdominal surgery without bowel function return
- History of inflammatory bowel disease or ischemic colitis 2
Drug Interactions
Administer CPS at least 3 hours before or after other oral medications to prevent binding and reduced absorption 2. Patients with gastroparesis may require 6-hour separation.
Electrolyte Monitoring
Monitor for:
- Hypokalemia (can develop with excessive use)
- Hypomagnesemia (due to nonselective binding)
- Hypercalcemia (theoretical risk from calcium exchange, though rare with CPS compared to patiromer)
The evidence base for CPS remains limited compared to newer agents (patiromer, sodium zirconium cyclosilicate), but it represents a cost-effective option for chronic hyperkalemia management, particularly in regions where newer agents are unavailable or cost-prohibitive 5, 7.